Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. by Berkhout, J. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/153643
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Pharmacokinetics and Penetration of Ceftazidime and Avibactam into
Epithelial Lining Fluid in Thigh- and Lung-Infected Mice
Johanna Berkhout,a Maria J. Melchers,b Anita C. van Mil,a Seyedmojtaba Seyedmousavi,b,d Claudia M. Lagarde,b
Wright W. Nichols,c Johan W. Moutonb,d*
Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlandsa; Department of Medical Microbiology, Radboud
University, Nijmegen Medical Center, Nijmegen, The Netherlandsb; AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USAc; Department of Medical Microbiology
and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlandsd
Ceftazidime and the-lactamase inhibitor avibactam constitute a new, potentially highly active combination in the battle
against extended-spectrum--lactamase (ESBL)-producing bacteria. To determine possible clinical use, it is important to know
the pharmacokinetic profiles of the compounds related to each other in plasma and the different compartments of infection in
experimentally infected animals and in humans. We used a neutropenic murine thigh infectionmodel and lung infectionmodel
to study pharmacokinetics in plasma and epithelial lining fluid (ELF). Mice were infected with ca. 106 CFU of Pseudomonas
aeruginosa intramuscularly into the thigh or intranasally to cause pneumonia and were given 8 different (single) subcutaneous
doses of ceftazidime and avibactam in various combined concentrations, ranging from 1 to 128 mg/kg of body weight in 2-fold
increases. Concomitant samples of serum and bronchoalveolar lavage fluid were taken at up to 12 time points until 6 h after ad-
ministration. Pharmacokinetics of both compounds were linear and dose proportional in plasma and ELF and were independent
of the infection type, with estimated half-lives (standard deviations [SD]) in plasma of ceftazidime of 0.28 (0.02) h and of avibac-
tam of 0.24 (0.04) h and volumes of distribution of 0.80 (0.14) and 1.18 (0.34) liters/kg. The ELF-plasma (area under the concen-
tration-time curve [AUC]) ratios (standard errors [SE]) were 0.24 (0.03) for total ceftazidime and 0.27 (0.03) for unbound cefta-
zidime; for avibactam, the ratios were 0.20 (0.02) and 0.22 (0.02), respectively. No pharmacokinetic interaction between
ceftazidime and avibactam was observed. Ceftazidime and avibactam showed linear plasma pharmacokinetics that were inde-
pendent of the dose combinations used or the infection site in mice. Assuming pharmacokinetic similarity in humans, this indi-
cates that similar dose ratios of ceftazidime and avibactam could be used for different types and sites of infection.
Ceftazidime (CAZ) is a potent -lactam antibiotic againstGram-negative bacteria in particular (1). However, since
more and more Gram-negative bacteria have emerged that carry
extended-spectrum-lactamases (ESBLs) (2, 3) and class C-lac-
tamases (4), resistance has led to difficulty in identifying -lactam
therapies thatwouldminimize the risk of resistance-related failure
(5). Moreover, Klebsiella pneumoniae carbapenemase (KPC) and
OXA-48 carbapenemase are narrowing treatment options against
Gram-negative bacteria even further (6–8). For this reason, alter-
natives have been sought. The use of-lactamase inhibitors seems
to be a reasonable approach, and combinations consisting of a
-lactam agent and a -lactamase inhibitor, such as piperacillin-
tazobactam and amoxicillin-clavulanic acid, are widely used. As-
traZeneca and Actavis (formerly Forest-Cerexa) are developing a
combination of ceftazidime (CAZ) with avibactam, a new prom-
ising -lactamase inhibitor, to overcome resistance caused by
-lactamases (9, 10). This combination has an extended spectrum
of activity and is active against Ambler class A extended-spectrum
-lactamases (ESBLs), KPC class A enzymes, class C (AmpC) en-
zymes, and some class D enzymes (11–15). In vitro studies have
shown that the drug MIC values for resistant clinical isolates, in-
cluding Pseudomonas aeruginosa, were drastically reduced in the
presence of this inhibitor and that the isolates thereby became
susceptible to ceftazidime (11, 16–19). Activity of the inhibitor in
vivo has been shown as well (see, e.g., reference 13).
As pneumonia is one of the leading causes of death in humans
(20) and treatments using several new compounds have failed in
patients with lower respiratory tract infections (21, 22), it is im-
portant to understand the mechanism of activity, including the
pharmacokinetic/pharmacodynamic (PK/PD) properties of the
drugs used for this indication. For the combination ceftazidime-
avibactam, concentrations of ceftazidime and avibactam in the
lungs relative to each other might be different from the relative
concentrations in plasma and therefore might result in bacterial
responses in lung infection that are different from those in infec-
tions in other tissues.
In the present study, we determined the pharmacokinetics of
ceftazidime and avibactam and concentration-time profiles of the
two compounds relative to each other in plasma and epithelial
lining fluid (ELF) of infected neutropenic mice. Both thigh infec-
tion and lung infection models were used, to determine whether
different kinds of infections would have different impacts on the
pharmacokinetic profiles of each compound. The pharmacoki-
netic parameter estimates and the penetration of the two com-
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pounds reported in this study are intended to serve as a basis to
determine exposure-response relationships.
(The results of this study were presented in part at the 53rd
Interscience Conference on Antimicrobial Agents and Chemo-
therapy, Denver, CO, 10 to 13 September 2013.)
MATERIALS AND METHODS
Drugs. Ceftazidime (CAZ; lot no. G263770; sodium carbonate blend;
potency, 77.2%) and avibactam (AVI; lot no. AFCH005151 [07113P028];
potency, 91.7%)were provided byAstraZeneca Pharmaceuticals LP,Wal-
tham, MA, USA. The drugs were reconstituted in sterile water to a stock
solution of 5,120 mg/liter, and further solutions were prepared in Muel-
ler-Hinton broth (Difco/Brunschwig Chemie, Amsterdam, The Nether-
lands).
Bacterial strains. Two P. aeruginosa strains (strains 7 and 19) were
used in the experiments. Both had ceftazidime MICs of 64 mg/liter and
ceftazidime-avibactam MICs of 4 mg/liter (with AVI at 4 mg/liter) as
defined in earlier checkerboard experiments (23).
Animals. Outbred female CD-1 mice (Charles River, The Nether-
lands), 7 to 8 weeks old and weighing 20 to 25 g, were used in the experi-
ments. Neutropenia was induced by two doses of cyclophosphamide in-
jected intraperitoneally 4 days (150mg/kg of body weight) and 1 day (100
mg/kg) before inoculation. The animals were housed under standard con-
ditions with drink and feed supplied ad libitum and were examined once
daily before and 2 to 3 times per day after immunosuppression. The ani-
mal studies were conducted in accordance with the recommendations of
the European Community (Directive 86/609/EEC, 24 November 1986),
and all animal procedures were approved by the Animal Welfare Com-
mittee of Radboud University (RU-DEC 2012-003).
Infection model and treatment. Pharmacokinetics were determined
in a thigh infection model (2 P. aeruginosa strains per animal, one inocu-
lated in the left thigh and the other in the right) and a lung infectionmodel
(1 strain per animal). In both cases, 0.05 ml of a bacterial suspension
consisting of approximately 106 to 107 bacteria was inoculated intramus-
cularly (thigh) or intranasallywith a syringe, the latter under conditions of
light anesthesia with isoflurane. Ceftazidime and avibactam were subcu-
taneously administered 2 h after infection with a single dose of 0.1 ml.
Eight dose combinations were used. For the thigh-infected animals,
the combinations of ceftazidime and avibactamwere 16/4, 8/1, 64/32, and
2/128 mg/kg. For the lung-infected mice, combinations of 32/16, 4/2,
128/8, and 1/64 mg/kg of the respective constituents were used. These
combinations were chosen in order to detect possible pharmacokinetic
interactions between the two compounds and to cover a wide range of
doses of each compound.
Concomitant samples of serum and bronchoalveolar lavage (BAL)
fluid were taken at 12 time points before (0 min) and after (5, 10, 20, 30,
45, 60, 90, 120, 180, 240, and 360min) administration of the combination
of ceftazidime and avibactam. Bronchoalveolar lavage (BAL) fluid and
blood were obtained immediately after mice were humanely sacrificed.
ELF was obtained using a technique described previously (24). In short,
after mice were sacrificed under conditions of isoflurane anesthesia fol-
lowed by cervical dislocation, they were secured on a plastic platform and
the trachea was exposed by a 1-cm-long incision on the ventral neck skin
for insertion of the cannula, which was sutured in place. Lungs were in-
FIG 1 Example of pharmacokinetic profiles of 2 different single doses of ceftazidime (codosed with avibactam) in plasma and ELF of neutropenic mice
with thigh infection (left panel, 16 mg/kg dose) or lung infection (right panel, 32 mg/kg dose). Filled and open squares, concentrations in plasma and ELF,
respectively, in the thigh model; filled and open circles, concentrations in plasma and ELF, respectively, in the lung model (each dose group consisted of
two mice).
FIG2 Example of pharmacokinetic profiles of 2 different single doses of avibactam (codosedwith ceftazidime) in plasma andELF of neutropenicmicewith thigh
infection (left panel, 32 mg/kg dose) or lung infection (right panel, 64 mg/kg). Filled and open squares, concentrations in plasma and ELF, respectively, in the
thigh model; filled and open circles, concentrations in plasma and ELF, respectively, in the lung model (each dose group consisted of two mice).
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stilled 4 times with 0.5 ml of sterile 0.9% saline solution, and the fluid was
aspirated immediately. The aspirates thus recovered were pooled, directly
placed on ice, and subsequently stored at80°C.
Antibiotic concentrationmeasurements. Plasmawas separated from
blood using a cooled centrifuge. Samples were split and stored at80°C.
Concentrations of ceftazidime and avibactam were determined by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) as described
previously in detail (25), with lower limits of quantitation (LLQ) of 1.5
ng/ml for ceftazidime and 1.8 ng/ml for avibactam. For ceftazidime, the
accuracy in plasma was 96.9%, with 2.53% precision (percent relative
standard deviation [%RSD]); the corresponding values in ELF were
100.4% and 3.84%, respectively. For avibactam, these values were 106.4%
accuracy with 7.33% precision in plasma and 98.7% accuracy with 6.57%
precision in ELF. Protein binding in plasma was 10% for ceftazidime as
described before (26) and seen in previous studies at our department (not
published); it was 8% for avibactam as determined in the equilibrium
dialysis chamber and analyzed via LC-MS/MS (27, 28). In ELF, protein
binding was considered negligible (29).
Concentrations of ceftazidime and avibactam in ELFwere determined by
using the ratio of the urea concentration in BAL fluid to the concentration in
plasma as measured with a modified enzymatic assay (QuantiChrom urea
assay kit DIUR-500; BioAssay Systems).
The apparent ELF volume was estimated by using urea as an endoge-
nous marker of ELF dilution and was calculated as described previously
(24, 30, 31). The drug concentration in ELF was subsequently calculated
as follows: drug concentrationELF  drug concentrationBAL fluid  urea
concentrationplasma/urea concentrationBAL fluid.
Pharmacokinetic analysis. Concentrations of ceftazidime and
avibactam in both plasma andELFwere plotted against time usingGraph-
pad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). PK param-
eters were estimated using Phoenix WinNonlin 2.1 (Certara, St. Louis,
MO, USA). Noncompartmental and one- and two-compartment models
were explored. The AUC was calculated using the log-linear trapezoidal
rule without extrapolation to infinity because of the very low detection
limit. Dose proportionality was determined following the standardmeth-
ods by determining the relationship between log (dose) and log (AUC) in
both the lung model and the thigh model following the power model
approach. Significant differences in pharmacokinetics between the thigh
model and the lung model were tested by comparing the slopes and the
intercepts of the regression lines of the relationships of the log (dose) to
the log (AUC).
RESULTS
Plasma concentrations of ceftazidime and avibactam were deter-
mined in 192 mice, and ELF concentrations could be determined
in 189 of these. No BAL fluid could be acquired from 3 mice
because of technical reasons. Urea levels could be determined in
all other samples. The mean dilution factor in BAL fluid was 11.6
(range, 4.3 to 144.2).
Figure 1 shows two examples of pharmacokinetic profiles of
ceftazidime in plasma and ELF from thigh- and lung-infected
mice after administration of doses of 16 and 32 mg/kg, respec-
tively, and Fig. 2 shows two similar examples of avibactam in
plasma and ELF. The curves for avibactam are comparable to
those for ceftazidime. From visual inspection of these and the
analogous graphs from all analyses, the results for both ceftazi-
TABLE 1 PK parameter estimates in plasma and ELF and ELF/plasma penetration ratios of ceftazidime and avibactam after a single subcutaneous
dose in neutropenic mice with thigh or lung infectiona
Dose (mg/kg) Infection
ELF AUC
(mg · h/liter) ELF t1/2 (h)
Plasma AUC
(mg · h/liter) Plasma t1/2 (h) Plasma Cl/F (liters/h)
ELF/plasma ratio
Total Freec
Ceftazidime
1 (64) Lung 0.04b 0.51 0.30 1.95
4 (2) Lung 0.11b 0.51b 1.60 0.29 2.50
32 (16) Lung 2.41 0.45 13.66 0.29 2.34 0.18 0.20
128 (8) Lung 15.50 0.41 68.52 0.25 1.87 0.23 0.25
2 (128) Thigh 0.08b 2.29b 1.25 0.30 1.60
8 (1) Thigh 1.31 0.27 4.37 0.27 1.83 0.30 0.33
16 (4) Thigh 2.27 0.27 7.64 0.24 2.09 0.30 0.33
64 (32) Thigh 7.54 0.54 36.40 0.29 1.76 0.21 0.23
Mean (SD) All 0.39 (0.12) 0.28 (0.02) 1.99 (0.30)
Mean (SE) All 0.24 (0.03) 0.27 (0.03)
Avibactam
2 (4) Lung 0.04b 0.346b 0.48 0.31 4.19
8 (128) Lung 0.54 0.26 2.64 0.27 3.02 0.20 0.22
16 (32) Lung 1.01 0.41 4.35 0.27 3.68 0.23 0.25
64 (1) Lung 4.12 0.32 19.41 0.24 3.29 0.21 0.23
1 (8) Thigh 0.10b 0.291b 0.26 0.18 3.87
4 (16) Thigh 0.40b 0.237b 1.31 0.19 3.05 0.30 0.33
32 (64) Thigh 2.31 0.40 10.66 0.27 3.00 0.22 0.24
128 (2) Thigh 7.99 0.30 51.46 0.23 2.49 0.16 0.17
Mean (SD) All 0.34 (0.07) 0.24 (0.04) 3.32 (0.55)
Mean (SE) All 0.22 (0.02) 0.24 (0.02)
a Doses in parentheses in column 1 represent the dose of the alternative compound (avibactam in the case of ceftazidime; ceftazidime in the case of avibactam). AUC, area under
the concentration-time curve; ELF, epithelial lining fluid; Cl/F, total body clearance relative to bioavailability; t1/2, half-life of the compound in the corresponding body fluid
sample.
b Values uncertain because of a low number of data points due to the LLQ in ELF. Those values were excluded for calculation of the mean.
c The proportion of protein binding for ceftazidime in plasma was 10% and in ELF was 0%; the proportion of protein binding for avibactam in plasma was 8% and in ELF was 0%.
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dime and avibactam indicated linear pharmacokinetics and no
systematic differences in the pharmacokinetic profiles of the
thigh- and lung-infected animals.
Table 1 summarizes the pharmacokinetic parameter estimates
for ceftazidime and avibactam in plasma and ELF. Concentrations
in ELF after the administration of 1, 2, and 4mg/kg were relatively
low or below the LLQ for most time points; estimates were there-
fore either not possible or not very accurate. The mean estimated
half-life in plasma of ceftazidime in the terminal phase was 0.28 h
(SD, 0.02 h), and that of avibactam was 0.24 h (SD, 0.04 h). Vol-
umes of distribution were 0.80 liters/kg (SD, 0.14 liters/kg) and
1.18 liters/kg (SD, 0.34 liters/kg), respectively (data not shown).
Figure 3 shows the dose proportionality of ceftazidime and
avibactam in the lung model and the thigh model and compari-
sons of the twomodels in plots of log dose versus log AUC follow-
ing the power model approach. Dose linearity and dose propor-
tionality results were similar for the two compounds; significant
differences between thigh- and lung-infected animals in dose pro-
portionality were not found for ceftazidime or for avibactam, ei-
ther in plasma or in ELF. In addition, there were no significant
differences between the intercepts of the thigh and lung regression
lines for the plasma concentrations of the two drugs in the two
models, regardless of the combination of doses chosen, further
confirming the absence of a difference in the pharmacokinetics of
the two compounds in the two infection models.
Since no significant pharmacokinetics differences between the
thigh model and lung model were observed, an overall relation-
ship between dose (mg/kg) and plasma AUC (mg · h/liter) after
a single dose of ceftazidime could be described as follows: log
AUC  0.294  0.9988  log (dose ceftazidime). The overall
relationship for avibactam was as follows: log AUC0.5896
1.070 log (dose avibactam).
Summarizing, the pharmacokinetics are linear and dose pro-
portional for both compounds and there are no significant differ-
ences between the thigh- and lung-infected animals in plasma
pharmacokinetics.
In general, concentrations in ELF were found to be around
4-fold lower than those in plasma (Fig. 1 and 2 and Table 1). The
concentration-time curves in ELF followed a pattern of linear
pharmacokinetics for both ceftazidime and avibactam. In similar-
ity to the findings in plasma, therewas dose linearity aswell as dose
proportionality for both ceftazidime and avibactam in ELF. Based
on the AUCs of the compounds in plasma and ELF, the overall
“penetration ratio” of ceftazidime in ELF (Table 1), was 0.24
(0.03) for the total drug concentrations. The ratios for the 1, 2, and
4 mg/kg doses were excluded, because the AUCs in ELF could be
determined only up to 1 h and therefore did not represent the
same time span as or a time span comparable to that in plasma.
Taking into account the protein binding of ceftazidime of 10% in
plasma (and no binding in ELF), the penetration ratio of free drug
was 0.27 (0.03) and was independent of the infection model. The
penetration ratio seemed to be slightly higher in the thigh infec-
tion model, but this was not significant. The values of the pene-
tration ratio for avibactam (Table 1) were 0.20 and 0.22, respec-
tively, comparable to those of ceftazidime, and no significant
differences between the thigh- and lung-infected models were
found.
FIG 3 Dose proportionality of ceftazidime (left panels) and avibactam (right panels) in plasma and ELF of infected mice after single doses. Filled symbols
represent plasma concentrations and open symbols concentrations in ELF. Squares represent concentrations in the thighmodel, circles represent concentrations
in the lungmodel, and every symbol represents twomice. AUC, area under the concentration-time curve; Dose, a single dose, administered subcutaneously; ELF,
epithelial lining fluid.
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DISCUSSION
In the present study, we studied the pharmacokinetic properties of
the combination of ceftazidime and avibactam in infected mice,
whether thigh or lung infected, to be able to compare pharmaco-
kinetics in two different types of infections. The aim was to look
for possible dose linearity and dose proportionality, the possible
influence of the pharmacokinetic behavior of each of the two com-
pounds on the other, and the possible influence of the type of
infection and the extent of penetration of the compounds in ELF
compared to plasma. The pharmacokinetics of both ceftazidime
and avibactam were linear and dose proportional as judged by
graphical plots of the data and by the outcomes of linear regres-
sion analysis. The similarity of the profiles in plasma and ELF
potentially reflects passive diffusion from plasma to ELF. For this
reason, plasma could be used as a surrogate for target attainment,
although the value of the pharmacodynamic target could be rela-
tively high for that reason.
Although a formal drug-drug interaction study was not per-
formed, based on the results of several different dose combina-
tionswe used encompassing virtually thewhole dose range of both
compounds, we did not find any evidence of drug-drug interac-
tions between ceftazidime and avibactam. Together with the dose
proportionality results, this indicates that exposures to both com-
pounds can be determined for pharmacodynamic analysis in mu-
rine infectionmodels in a relatively straightforwardmanner with-
out the need to include interactions between the two compounds.
There were no differences in the pharmacokinetic parameter
estimates for thigh- or lung-infectedmice as evidenced by the dose
proportionality analysis; thus, the type of infection the mice suf-
fered from did not influence pharmacokinetics. The half-life val-
ues in plasma for both drugs were relatively short, as would be
expected in mice, and within the same range. The half-life of cef-
tazidime as determined in this studywas comparable to that found
in other studies (32–34) and in our own laboratory in earlier ex-
periments (35), although the half-life found by Fantin et al. (32)
was slightly longer. However, the pharmacokinetic analysis in the
study reported here was far more extensive than in the previous
analyses, and the concentration-time curves are reproducible and
clearly dose proportional. We therefore conclude that the esti-
mates presented here are representative.
The levels of penetration of ceftazidime and avibactam in ELF
were comparable andwere close to 25% for both compounds. The
data regarding penetration of ceftazidime and avibactam intomu-
rine ELF reported here are similar to the results reported byHous-
man et al. (36), who showed that simulated human exposures of
ceftazidime and avibactam were bactericidal to ceftazidime-resis-
tant P. aeruginosa infecting the lungs of neutropenic mice. The
AUC-based penetration ratios were slightly lower than those
found in humans byNicolau et al. (37), whichwere approximately
40% for each compound. However, it is noted that these ELF/
plasma AUC ratios reported for human subjects were calculated
using total plasma concentrations of ceftazidime and avibactam.
This means that the ratio in humans determined on the basis of
free plasma concentrations would have been slightly higher than
those reported, if adjusted for the proportion of compound
bound to protein. ELF/plasma ratios of ceftazidime alone in hu-
mans have been measured previously; Cazzola et al. (38) found a
ratio of about 10%, measured by microbiological assay, and the
group of Boselli (39) found levels around 21% in critically ill hu-
man patients, measured with HPLC.
In conclusion, we foundno significant differences for the phar-
macokinetics of subcutaneously administered ceftazidime or
avibactam in plasma and ELF in thigh- or lung-infected neutro-
penic mice and the pharmacokinetics of the two compounds were
proportional with respect to the dose. The ratios of the concentra-
tions of the two drugs in plasma versus ELF were close to 25% and
constant, were independent of the doses administered, and, based
on pharmacokinetic studies in humans as mentioned above, were
therefore comparable to or lower than thosemeasured in humans.
The higher penetration in humans minimizes the risk of under-
dosing in patients when extrapolating from mouse data.
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